In August 2025, Nyxoah received U.S. FDA approval for the Genio® system and launched commercialization. In Q4 2025, the company reported gross revenue of €6.3 million (347% YoY growth), with 145 surgeons trained and 57 accounts activated in the U.S. In September 2025, the company expanded into the Middle East with first implants in Abu Dhabi, Dubai, and Kuwait. The company guided for 25% sequential quarterly U.S. revenue growth in Q1 and Q2 2026.
Company Overview (Updated April 2026)
Nyxoah SA is a medical technology company headquartered in Mont-Saint-Guibert, Belgium. Founded in 2009, the company is dedicated to developing and commercializing innovative solutions for Obstructive Sleep Apnea (OSA), the world's most common sleep disordered breathing condition associated with increased mortality risk and cardiovascular comorbidities. The company trades on Euronext Brussels and Nasdaq under the ticker NYXH.
Mission: To transform the treatment of OSA by providing patient-centered neurostimulation solutions that enAble restful nights and empower patients to live life to its fullest.
Corporate History and Regulatory Milestones (2009-2025)
Founding and CE Mark (2009-2019)
- 2009: Company founded in Belgium to develop neurostimulation therapies for OSA
- 2019: Genio system received CE Mark approval in Europe following positive clinical data
Pivotal Trials and FDA Approval (2020-2025)
- 2023: DREAM pivotal study demonstrated Genio's clinical efficacy in both supine and non-supine positions, differentiating it from competitors
- August 2025: Received FDA Premarket Approval (PMA) for the Genio system in the United States
- September 2025: First U.S. commercial implants performed; secured reimbursement from Medicare and major commercial payors
- September 2025: Expanded Middle East presence with first Genio implant in Abu Dhabi and new centers in Dubai and Kuwait
Core Product: Genio® System
Technology Overview
The Genio® system is a leadless, battery-free, bilateral hypoglossal neurostimulation therapy for moderate-to-severe OSA:
- Leadless Design: Unlike competitors, Genio uses a single small implant under the chin without leads running to a chest-implanted battery
- Battery-Free: Powered wirelessly via an external patch worn during sleep, eliminating need for surgical battery replacement
- Bilateral Stimulation: Stimulates both hypoglossal nerves to treat tongue base collapse in both supine and non-supine positions
- Patient-Controlled: Patients activate therapy via smartphone app and wear a disposable adhesive patch eACH night
Clinical Indications: Moderate-to-severe OSA in patients who are unable to tolerate or benefit from Continuous Positive Airway Pressure (CPAP)
Clinical Evidence
- DREAM Study: Pivotal trial published demonstrating efficacy in both supine and non-supine sleeping positions
- BETTER SLEEP Study: Supported CE Mark expansion and clinical validation
- Patient Outcomes: First U.S. patients reported positive results with consistent reimbursement from major payors
Financial Performance (2025)
Q4 2025 Results (First Full U.S. Commercial Quarter)
- Gross Revenue: €6.3 million (before €0.7 million deferred revenue from disposable patches)
- Net Revenue: €5.6 million (347% year-over-year growth)
- U.S. Gross Revenue: €3.9 million
- U.S. Net Revenue: €3.5 million
- Gross Margin: Approximately 64%
Full Year 2025 Results
- Gross Revenue: €11.0 million (before €1.0 million deferred revenue)
- Net Revenue: €10.0 million (122% year-over-year growth)
- U.S. Gross Revenue: €4.2 million
- U.S. Net Revenue: €3.7 million
- Full Year Gross Margin: Approximately 63%
- Operating Loss: €83.5 million (vs €58.8 million in 2024)
- Net Loss: €90.1 million
- Cash Position (Dec 31, 2025): €48.0 million
2026 Revenue Guidance
- Q1 2026 U.S. Net Revenue: Expected to grow approximately 25% over Q4 2025
- Q2 2026 U.S. Net Revenue: Expected to grow approximately 25% over Q1 2026
- International Revenue: Expected to follow typical seasonal pattern
U.S. Commercial Launch and Global Expansion
U.S. Market Entry (2025)
- Launch Strategy: Two-pronged approach targeting high-volume hypoglossal nerve stimulation implanting centers while educating referral networks of sleep physicians
- Physician Training: 145 surgeons trained as of December 31, 2025
- Account Activation: 57 accounts activated in the U.S.
- Reimbursement: Consistently reimbursed by both commercial payors and Medicare; new interim C-codes issued by CMS for HGNS procedures
International Expansion
- Europe: CE Marked; established commercial presence
- Middle East (2025): First implant in Abu Dhabi (September 2025); expanded to Dubai and Kuwait with world-class healthcare partnerships
- Manufacturing: Expanding manufacturing footprint to support global growth
Competitive Landscape
Primary Competitors:
- Inspire Medical Systems: Market leader with unilateral hypoglossal nerve stimulation system (Inspire II) with chest-implanted battery and leads
- LivaNova: Developing competing HGNS technology
- ResMed, Somnics, Cryosa: Alternative OSA treatment devices
Competitive Differentiation:
- Only Leadless & Battery-Free System: No chest-implanted battery, no leads, no need for replacement surgery
- Bilateral Stimulation: Treats both sides of the tongue vs. unilateral competitors
- Supine & Non-Supine Efficacy: DREAM study showed efficacy regardless of sleeping position
- Less Invasive Procedure: Shorter implant time and simpler surgical workflow
Analyst Ratings and Market Data (2026)
- Consensus Rating: Buy / Strong Buy (4 analysts)
- Average Price Target: $10.00 - $11.25
- Current Stock Price: ~$3.38 (April 2026)
- Market Cap: ~$153 million (March 2026)
- 52-Week Range: $3.41 - $11.72
Leadership Team
Executive Leadership
Chief Executive Officer: Olivier Taelman
- Led company through FDA approval and U.S. commercial launch
- Previously commented on strong Q4 2025 momentum and expanded sales force
Company Information
Corporate Details
Legal Name: Nyxoah SA
Founded: 2009
Headquarters: Rue de l'Industrie 12, 1435 Mont-Saint-Guibert, Belgium
Stock Exchange: Euronext Brussels / Nasdaq
Ticker Symbol: NYXH
Status: Public company
Industry: Medical Devices - Therapeutic Devices / Sleep Medicine / Neurostimulation
Employees: 191 (as of 2025)
Market Cap: ~$153 million (March 2026)
Contact Information
Investor Relations: investors.nyxoah.com
Website: www.nyxoah.com
Keywords: Nyxoah, NYXH, Genio, OSA, obstructive sleep apnea, hypoglossal neurostimulation, leadless, battery-free, bilateral stimulation, Olivier Taelman, Mont-Saint-Guibert, Belgium, FDA approval, PMA, DREAM study, BETTER SLEEP, U.S. commercial launch, Medicare reimbursement, Middle East expansion, 2009 founded
